Same Indication

Nivolumab vs Trastuzumab Deruxtecan

Nivolumab vs Trastuzumab Deruxtecan: Overview

This comparison examines the pharmacological differences between Nivolumab and Trastuzumab Deruxtecan.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Nivolumab — 27 days.

Chemical Properties

Type: Nivolumab — Antibody; Trastuzumab Deruxtecan — Antibody drug conjugate.